ELVN

Enliven Therapeutics
$52.74
−$0.22 (−0.41%)Jul 27, 2026
5.9NeutralMoatMint rating

MoatMint rates Enliven Therapeutics (ELVN) 5.9 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 0.8 out of 10.

Key metrics

The numbers that frame ELVN today
Market cap
$3.21B
P/E (TTM)
-32.5
EV / FCF
-47.1
ROIC
-27.7%
Div yield
0%
Debt / equity
0.0
52wk Low
$14.79
52wk High
$55.79

ELVN stock rating

How ELVN scores on quality, value, growth, momentum and financial health
5.9out of 10
Neutral overallHealthy business, expensive priceTop 41% of ~5,000 US stocks
QualityPoor0.8/10
GrowthGreat8.5/10
MomentumGreat9.6/10
ValueFair3.3/10
Financial HealthGreat8.5/10

Growth

Revenue and earnings trend for ELVN
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about ELVN
Is Enliven Therapeutics a good buy?
Hold. Enliven Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks excellent, which supports the long-term business case. We think Enliven Therapeutics is selling at a high price.
What is the market capitalization of ELVN?
Enliven Therapeutics's market capitalization is $3.21B.
What is the P/E ratio for ELVN stock?
Enliven Therapeutics's current P/E ratio is -32.5.
What is the 52-week high for ELVN stock?
The 52-week high for Enliven Therapeutics is $55.79. The current close of $52.74 is 5.5% below that high.
What is the 52-week low for ELVN stock?
The 52-week low for Enliven Therapeutics is $14.79. The current close of $52.74 is 256.7% above that low.
Does ELVN stock pay dividends?
Enliven Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for ELVN?
Enliven Therapeutics's Debt / Equity ratio is 0.